PharmaCord Receives Investment from Permira
Summary
The amount of the deal, which is subject to customary regulatory approvals, is expected to close by the fourth quarter of 2024, was not disclosed. The company intends to use the funds to expand operations and its business reach. Founder and Chief Executive Officer Nitin Sahney and the management team will continue to lead PharmaCord and will remain significant investors in the company alongside the Permira funds. PharmaCord is a pharma services company that serves as a commercialization partner for life sciences organizations with the goal of enhancing the patient experience. Its comprehensive solutions support the patient journey for specialty medications through a range of services that raise awareness, facilitate access to treatment, improve affordability and promote therapy adherence.